Ipca Laboratories（524494）株式概要製薬会社であるイプカ・ラボラトリーズ・リミテッドは、インド、ヨーロッパ、アフリカ、アメリカ大陸、アジア、CIS、オーストラレーシアにおいて、さまざまな治療分野向けの製剤や原薬（API）を製造・販売している。 詳細524494 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績4/6財務の健全性5/6配当金3/6報酬収益は年間17.33%増加すると予測されています 過去1年間で収益は54.7%増加しました リスク分析不安定な配当実績 すべてのリスクチェックを見る524494 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,257 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG485,257 investors already sharing narrativesYour Fair Value₹Current Price₹1.89k9.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0159b2016201920222025202620282031Revenue ₹159.1bEarnings ₹18.8bAdvancedSet Fair ValueView all narrativesIpca Laboratories Limited 競合他社Gland PharmaSymbol: NSEI:GLANDMarket cap: ₹416.7bAjanta PharmaSymbol: NSEI:AJANTPHARMMarket cap: ₹431.2bJ. B. Chemicals & PharmaceuticalsSymbol: BSE:506943Market cap: ₹387.3bEmcure PharmaceuticalsSymbol: NSEI:EMCUREMarket cap: ₹341.8b価格と性能株価の高値、安値、推移の概要Ipca Laboratories過去の株価現在の株価₹1,891.2552週高値₹1,909.0052週安値₹1,252.95ベータ0.0491ヶ月の変化21.96%3ヶ月変化28.83%1年変化28.29%3年間の変化140.92%5年間の変化73.72%IPOからの変化2,340.32%最新ニュースReported Earnings • Jul 11Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹96.5b (up 7.9% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year.お知らせ • Jul 02Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026, at 15:30 Indian Standard Time.お知らせ • Jun 27Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million.Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million on June 26, 2026. The consideration consists of common equity of Ipca Laboratories Limited at a ratio of 0.035 per common equity and convertible preferred equity of Krebs Biochemicals & Industries Limited. As part of consideration, INR 736.32 million is paid towards redeemable preference shares convertible preferred equity and INR 612 million is paid towards common equity of Krebs Biochemicals & Industries Limited. Upon completion, Ipca Laboratories Limited will own 100% stake in Krebs Biochemicals & Industries Limited. Upon merger, Krebs Biochemicals & Industries Limited would get merged with Ipca Laboratories Limited. The transaction is subject to approval of merger agreement by target board and approval of offer by acquirer board. The deal has been approved by the board. The Appointed Date for the Scheme is 1st April, 2026 and it shall be operative from the Effective Date upon receipt of all the consents and approvals as defined in the Scheme.New Risk • Jun 05New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Declared Dividend • Jun 01Dividend of ₹6.00 announcedShareholders will receive a dividend of ₹6.00. Ex-date: 7th August 2026 Payment date: 1st January 1970 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (6% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 30Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹98.2b (up 9.8% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year and the company’s share price has also increased by 28% per year.最新情報をもっと見るRecent updatesReported Earnings • Jul 11Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹96.5b (up 7.9% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year.お知らせ • Jul 02Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026, at 15:30 Indian Standard Time.お知らせ • Jun 27Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million.Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million on June 26, 2026. The consideration consists of common equity of Ipca Laboratories Limited at a ratio of 0.035 per common equity and convertible preferred equity of Krebs Biochemicals & Industries Limited. As part of consideration, INR 736.32 million is paid towards redeemable preference shares convertible preferred equity and INR 612 million is paid towards common equity of Krebs Biochemicals & Industries Limited. Upon completion, Ipca Laboratories Limited will own 100% stake in Krebs Biochemicals & Industries Limited. Upon merger, Krebs Biochemicals & Industries Limited would get merged with Ipca Laboratories Limited. The transaction is subject to approval of merger agreement by target board and approval of offer by acquirer board. The deal has been approved by the board. The Appointed Date for the Scheme is 1st April, 2026 and it shall be operative from the Effective Date upon receipt of all the consents and approvals as defined in the Scheme.New Risk • Jun 05New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Declared Dividend • Jun 01Dividend of ₹6.00 announcedShareholders will receive a dividend of ₹6.00. Ex-date: 7th August 2026 Payment date: 1st January 1970 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (6% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 30Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹98.2b (up 9.8% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year and the company’s share price has also increased by 28% per year.お知らせ • May 30Ipca Laboratories Limited Recommends Dividend for the Financial Year Ended March 31, 2026Ipca Laboratories Limited at its Board of Directors meeting holed on May 29, 2026 announced that the Board has recommended a dividend of INR 6/- per share of INR 1/- each (600%) for the financial year ended 31st March, 2026. This dividend recommended is subject to the approval of the shareholders at the ensuing Annual General Meeting. The Company has fixed 7th August, 2026 as the Record Date for the Members entitlement of dividend, if approved at the ensuing Annual General Meeting.お知らせ • May 04Ipca Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Ipca Laboratories Limited announced that they will report Q4, 2026 results on May 29, 2026Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹12.86 (vs ₹9.78 in 3Q 2025)Third quarter 2026 results: EPS: ₹12.86 (up from ₹9.78 in 3Q 2025). Revenue: ₹24.1b (up 7.5% from 3Q 2025). Net income: ₹3.26b (up 32% from 3Q 2025). Profit margin: 14% (up from 11% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 21% per year.お知らせ • Jan 22Ipca Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026Ipca Laboratories Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 13, 2026Reported Earnings • Nov 14Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹11.14 (up from ₹9.05 in 2Q 2025). Revenue: ₹25.8b (up 9.7% from 2Q 2025). Net income: ₹2.83b (up 23% from 2Q 2025). Profit margin: 11% (up from 9.7% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 20% per year.お知らせ • Oct 17Ipca Laboratories Limited to Report Q2, 2026 Results on Nov 13, 2025Ipca Laboratories Limited announced that they will report Q2, 2026 results on Nov 13, 2025Reported Earnings • Aug 12First quarter 2026 earnings released: EPS: ₹9.19 (vs ₹7.58 in 1Q 2025)First quarter 2026 results: EPS: ₹9.19 (up from ₹7.58 in 1Q 2025). Revenue: ₹23.1b (up 10% from 1Q 2025). Net income: ₹2.33b (up 21% from 1Q 2025). Profit margin: 10% (in line with 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 14% per year.Upcoming Dividend • Jul 29Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 05 August 2025. Payment date: 10 September 2025. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.8%).お知らせ • Jul 24Ipca Laboratories Limited to Report Q1, 2026 Results on Aug 11, 2025Ipca Laboratories Limited announced that they will report Q1, 2026 results on Aug 11, 2025Reported Earnings • Jul 11Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₹29.08 (up from ₹21.57 in FY 2024). Revenue: ₹90.3b (up 17% from FY 2024). Net income: ₹7.38b (up 35% from FY 2024). Profit margin: 8.2% (up from 7.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • Jul 06Ipca Laboratories Limited, Annual General Meeting, Aug 11, 2025Ipca Laboratories Limited, Annual General Meeting, Aug 11, 2025, at 15:30 Indian Standard Time.Declared Dividend • May 31Final dividend of ₹2.00 announcedDividend of ₹2.00 is the same as last year. Ex-date: 5th August 2025 Payment date: 1st January 1970 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (14% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 103% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 30Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₹29.08 (up from ₹21.57 in FY 2024). Revenue: ₹90.3b (up 17% from FY 2024). Net income: ₹7.38b (up 35% from FY 2024). Profit margin: 8.2% (up from 7.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.お知らせ • May 14Ipca Laboratories Limited to Report Q4, 2025 Results on May 29, 2025Ipca Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025お知らせ • Mar 03Ipca Laboratories Limited Appoints Saidutta Nanda as President - Human ResourcesIpca Laboratories Limited informed that Mr. Saidutta Nanda has joined the Company as President - Human Resources with effect from 3rd March, 2025. Mr. Saidutta Nanda, aged 48 years has completed his Master of Business Administration from Institute of Management Studies, Devi Ahilya Vishwavidyalay, Indore. Mr. Nanda brings with him a professional experience of over 24 years. He started his career with Cadila Pharmaceuticals in the year 1999. Prior to joining us, he was associated with Macleods Pharmaceuticals Limited as President - Human Resources. He will be responsible for leading all the activities related to the Human Resources Division of the Company.Reported Earnings • Feb 14Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: EPS: ₹9.78 (up from ₹7.09 in 3Q 2024). Revenue: ₹22.5b (up 9.4% from 3Q 2024). Net income: ₹2.48b (up 38% from 3Q 2024). Profit margin: 11% (up from 8.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • Jan 28Ipca Laboratories Limited to Report Q3, 2025 Results on Feb 13, 2025Ipca Laboratories Limited announced that they will report Q3, 2025 results on Feb 13, 2025Price Target Changed • Dec 04Price target increased by 7.8% to ₹1,564Up from ₹1,452, the current price target is an average from 19 analysts. New target price is 5.0% above last closing price of ₹1,489. Stock is up 32% over the past year. The company is forecast to post earnings per share of ₹34.84 for next year compared to ₹21.57 last year.Reported Earnings • Nov 18Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2025 results: EPS: ₹9.62 (up from ₹5.72 in 2Q 2024). Revenue: ₹23.8b (up 17% from 2Q 2024). Net income: ₹2.29b (up 58% from 2Q 2024). Profit margin: 9.6% (up from 7.1% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Declared Dividend • Nov 16Dividend of ₹2.00 announcedDividend of ₹2.00 is the same as last year. Ex-date: 25th November 2024 Payment date: 10th December 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 125% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Oct 24Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024Ipca Laboratories Limited announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Sep 20Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024Ipca Laboratories Limited announced that The second term of appointment of Dr. (Ms.) Manisha Premnath as an independent director of the Company is ending on September 20, 2024. Accordingly, she ceases to be an independent director of the Company with effect from September 21, 2024. Consequently, she also ceases to be member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee of the Board with effect from September 21, 2024. Consequent to the above, the revised composition of the Board of Directors of the Company with effect from September 21, 2024 is as follows: Mr. Premchand Godha, Executive Chairman. Mr. A.K. Jain, Managing Director /CFO. Mr. Pranay Godha, Managing Director /CEO. Mr. Prashant Godha, Executive Director. Mr. Kamal Kishore Seth, Independent Director. Dr. Narendra Mairpady, Independent Director. Dr. (Ms.) Swati Patankar, Independent Director. Mr. Vivek Shiralkar, Independent Director.Price Target Changed • Aug 17Price target increased by 8.6% to ₹1,320Up from ₹1,216, the current price target is an average from 18 analysts. New target price is approximately in line with last closing price of ₹1,335. Stock is up 52% over the past year. The company is forecast to post earnings per share of ₹35.26 for next year compared to ₹21.57 last year.お知らせ • Aug 14Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent DirectorIpca Laboratories Limited announced that at its AGM held on 13 August 2024, the shareholders approved appointment of Mr. Vivek Shiralkar as an independent director of the company for a period of five consecutive years from 29 May 2024 to 28 May 2029.Upcoming Dividend • Jul 30Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 06 August 2024. Payment date: 10 September 2024. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%).お知らせ • Jul 24Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024Ipca Laboratories Limited announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • Jul 20Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: EPS: ₹21.57 (up from ₹18.58 in FY 2023). Revenue: ₹77.1b (up 23% from FY 2023). Net income: ₹5.47b (up 16% from FY 2023). Profit margin: 7.1% (down from 7.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.お知らせ • Jul 12Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024, at 15:30 Indian Standard Time.Board Change • Jul 05Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Swati Patankar was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 30Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024Ipca Laboratories Limited has recommended a final dividend of INR 21 per share (200%) for the financial year ended March 31, 2024. This dividend is subject to the approval of the shareholders at the upcoming annual general meeting.Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)Full year 2024 results: EPS: ₹25.82 (up from ₹18.58 in FY 2023). Revenue: ₹78.3b (up 25% from FY 2023). Net income: ₹5.47b (up 16% from FY 2023). Profit margin: 7.0% (down from 7.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • May 09Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024Ipca Laboratories Limited announced that they will report Q4, 2024 results on May 29, 2024お知らせ • Mar 30+ 1 more updateIpca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent DirectorIpca Laboratories Limited announced that second term of appointment of Mr. Anand T. Kusre as an independent director of the Company is coming to an end on 31 March, 2024. Accordingly, he ceases to be an independent director of the Company with effect from 1 April, 2024. Consequent to the above, the revised composition of the Board of Directors of the Company with effect from 1st April, 2024 is as under: Mr. Premchand Godha Executive Chairman, Mr. A.K. Jain Managing Director /CFO, Mr. Pranay Godha Managing Director /CEO, Mr. Prashant Godha Executive Director, Dr. (Ms.) Manisha Premnath Independent Director, Mr. Kamal Kishore Seth Independent Director, Dr. Narendra Mairpady Independent Director and Dr. (Ms.) Swati Patankar Independent Director.Price Target Changed • Feb 17Price target increased by 9.1% to ₹1,097Up from ₹1,006, the current price target is an average from 18 analysts. New target price is 12% below last closing price of ₹1,241. Stock is up 49% over the past year. The company is forecast to post earnings per share of ₹25.84 for next year compared to ₹18.58 last year.Reported Earnings • Feb 15Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: ₹7.09 (up from ₹4.25 in 3Q 2023). Revenue: ₹20.8b (up 34% from 3Q 2023). Net income: ₹1.80b (up 67% from 3Q 2023). Profit margin: 8.7% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Jan 23Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024Ipca Laboratories Limited announced that they will report Q3, 2024 results on Feb 14, 2024Recent Insider Transactions • Nov 22CFO, MD & Executive Director recently sold ₹22m worth of stockOn the 17th of November, Ajit Kumar Jain sold around 20k shares on-market at roughly ₹1,082 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ajit Kumar's only on-market trade for the last 12 months.Price Target Changed • Nov 17Price target increased by 9.7% to ₹987Up from ₹900, the current price target is an average from 18 analysts. New target price is 8.6% below last closing price of ₹1,079. Stock is up 25% over the past year. The company is forecast to post earnings per share of ₹27.89 for next year compared to ₹18.58 last year.Upcoming Dividend • Nov 15Upcoming dividend of ₹2.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 22 November 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 10% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).Reported Earnings • Nov 11Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: EPS: ₹5.72 (up from ₹5.67 in 2Q 2023). Revenue: ₹20.7b (up 30% from 2Q 2023). Net income: ₹1.45b (flat on 2Q 2023). Profit margin: 7.0% (down from 9.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • Oct 26Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023Ipca Laboratories Limited announced that they will report Q2, 2024 results on Nov 10, 2023お知らせ • Oct 17Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)Ipca Laboratories Limited announced that Mr. Hitesh Kumar Maheshwari has joined the Company as President R&D (Formulations) with effect from 16 October, 2023. Mr. Hitesh Maheshwari, aged 49 years has completed his B. Pharm from Devi Ahilya Vishwavidyalaya, Indore and M.Pharm from Panjab University, Chandigarh. Mr. Maheshwari brings with him a professional experience of over 24 years. He started his career with Ranbaxy Laboratories in the year 1999 and thereafter worked with Zydus Cadila Healthcare Ltd., Hikma Pharmaceuticals Ltd., Astron Research Ltd. and Macleods Pharmaceuticals Ltd. Prior to joining us, he was associated with Torrent Pharmaceuticals Ltd. as Executive Director and Head R&D (Formulations). He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company.お知らせ • Jul 24Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023Ipca Laboratories Limited announced that they will report Q1, 2024 results on Aug 10, 2023Reported Earnings • Jul 14Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: ₹18.58 (down from ₹34.85 in FY 2022). Revenue: ₹62.5b (up 7.2% from FY 2022). Net income: ₹4.71b (down 47% from FY 2022). Profit margin: 7.5% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 26 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Jul 06Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023, at 15:30 Indian Standard Time.Reported Earnings • May 30Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: ₹18.58 (down from ₹34.85 in FY 2022). Revenue: ₹63.7b (up 9.3% from FY 2022). Net income: ₹4.71b (down 47% from FY 2022). Profit margin: 7.4% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • May 13Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023Ipca Laboratories Limited announced that they will report Q4, 2023 results at 12:08 PM, Indian Standard Time on May 29, 2023Price Target Changed • Apr 30Price target decreased by 8.1% to ₹851Down from ₹925, the current price target is an average from 19 analysts. New target price is 20% above last closing price of ₹710. Stock is down 30% over the past year. The company is forecast to post earnings per share of ₹23.52 for next year compared to ₹34.85 last year.Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹701, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Pharmaceuticals industry in India. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹291 per share.Reported Earnings • Feb 15Third quarter 2023 earnings: EPS misses analyst expectationsThird quarter 2023 results: EPS: ₹4.25 (down from ₹7.76 in 3Q 2022). Revenue: ₹15.5b (up 8.1% from 3Q 2022). Net income: ₹1.08b (down 45% from 3Q 2022). Profit margin: 7.0% (down from 14% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 33%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 21Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023Ipca Laboratories Limited announced that they will report Q3, 2023 results on Feb 14, 2023お知らせ • Dec 20Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million on December 16, 2022. Ipca Laboratories Limited (BSE:524494) now holds 58.88% of the paid-up equity share capital of said company. Ipca Laboratories Limited (BSE:524494) completed the acquisition of additional 6.53% stake in Trophic Wellness Pvt. Ltd. on December 16, 2022.Major Estimate Revision • Nov 18Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ₹64.0b to ₹62.9b. EPS estimate also fell from ₹33.10 per share to ₹27.90 per share. Net income forecast to grow 43% next year vs 42% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹1,000 to ₹964. Share price was steady at ₹865 over the past week.Upcoming Dividend • Nov 16Upcoming dividend of ₹4.00 per shareEligible shareholders must have bought the stock before 22 November 2022. Payment date: 07 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%).Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 6 highly experienced directors. Additional Independent Director Narendra Mairpady was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹5.67 (down from ₹9.87 in 2Q 2022). Revenue: ₹16.4b (up 6.0% from 2Q 2022). Net income: ₹1.44b (down 43% from 2Q 2022). Profit margin: 8.8% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 11Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022Ipca Laboratories Limited announced that its Board has declared an interim dividend of INR 4 per share (400%) for the financial year 2022-23. Kindly note that vide company letter dated November 2, 2022, it had already informed that 23rd November, 2022 has been fixed as the Record Date for ascertaining the members entitlement of said interim dividend now declared which will be paid by the company to the eligible shareholders on or before 7th December, 2022.お知らせ • Nov 03Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022Ipca Laboratories Limited announced that they will report Q2, 2023 results on Nov 11, 2022お知らせ • Oct 21Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent DirectorIpca Laboratories Limited appointed Dr. Narendra Mairpady (DIN 00536905) as an Additional Director of the Company with effect from 20th October, 2022. He is also appointed as an Independent Director of the Company for a period of 5 years from 20th October, 2022 till 19th October, 2027. This appointment is subject to the approval of shareholders. Dr. Narendra Mairpady, aged 68 years, is a Commerce Graduate and also holds a Bachelor of Law Degree from Mysore University. He is also a certified CAIIB from the Institure of Banking. He has also obtained his Doctor Letters from Hindustan University, Chennai and Kalpagam University, Coimbatore. Consequent to the above, the revised composition of the Board of Directors of the Company with effect from 20th October, 2022 will be: Mr. Premchand Godha- Chairman & Managing Director /CEO; Mr. A.K. Jain- Joint Managing Director /CFO; Mr. Pranay Godha- Executive Director; Mr. Prashant Godha Executive Director; Mr. Anand T. Kusre - Independent Director; Dr. (Ms.) Manisha Premnath Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. Narendra Mairpady - Independent Director. The Board has also re-constituted its following committees with effect from 20th October, 2022 and the revised Board Committees will now comprise of the following Board Members: Audit Committee; Mr. Anand T. Kusre - Chairman of the Committee /Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. Narendra Mairpady - Independent Director; Mr. Prashant Godha - Executive Director; Nomination and Remuneration Committee: Mr. Anand T. Kusre Chairman of the Committee /Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. (Ms.) Manisha Premnath - Independent Director; Dr. Narendra Mairpady - Independent Director.Recent Insider Transactions • Sep 21Insider recently sold ₹1.7m worth of stockOn the 15th of September, E. Babu sold around 2k shares on-market at roughly ₹874 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 EPS estimate fell from ₹37.84 to ₹32.15 per share. Revenue forecast steady at ₹64.0b. Net income forecast to grow 24% next year vs 30% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹1,063 to ₹1,038. Share price fell 6.7% to ₹926 over the past week.お知らせ • Aug 12Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022Ipca Laboratories Limited at annual general meeting held on 10 August 2022, approved the confirmation of Interim dividend of INR 8/- per equity share as final dividend for the financial year ended 31st March, 2022.Buying Opportunity • Aug 08Now 20% undervaluedOver the last 90 days, the stock is up 3.9%. The fair value is estimated to be ₹1,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.お知らせ • Aug 05Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent DirectorIpca Laboratories Limited announced demise of Independent Director, Mr. Dev Parkash Yadava on the evening of August 2, 2022, at Mumbai. Mr. Yadava was the Non-Executive and Independent Director of the Company since April 2012.お知らせ • Jul 30Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022Ipca Laboratories Limited announced that they will report Q1, 2023 results at 12:15 PM, Indian Standard Time on Aug 10, 2022Buying Opportunity • Jul 21Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 2.1%. The fair value is estimated to be ₹1,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.Reported Earnings • Jul 16Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: ₹34.85 (down from ₹45.01 in FY 2021). Revenue: ₹58.3b (up 7.6% from FY 2021). Net income: ₹8.84b (down 22% from FY 2021). Profit margin: 15% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 28 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 10%, compared to a 12% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 08Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022, at 15:30 Indian Standard Time.Buying Opportunity • Jun 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be ₹1,132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.Price Target Changed • May 30Price target decreased to ₹1,067Down from ₹1,162, the current price target is an average from 19 analysts. New target price is 18% above last closing price of ₹901. Stock is down 13% over the past year. The company is forecast to post earnings per share of ₹37.13 for next year compared to ₹34.85 last year.Reported Earnings • May 26Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: ₹34.85 (down from ₹45.01 in FY 2021). Revenue: ₹58.3b (up 7.5% from FY 2021). Net income: ₹8.84b (down 22% from FY 2021). Profit margin: 15% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 8.8%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 6 highly experienced directors. Independent Director Kamal Seth was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Mar 23CFO, Joint MD & Executive Director recently sold ₹21m worth of stockOn the 17th of March, Ajit Kumar Jain sold around 20k shares on-market at roughly ₹1,027 per share. This was the largest sale by an insider in the last 3 months. Ajit Kumar has been a seller over the last 12 months, reducing personal holdings by ₹45m.Major Estimate Revision • Feb 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from ₹45.80 to ₹37.92 per share. Revenue forecast steady at ₹58.7b. Net income forecast to grow 22% next year vs 23% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹1,280 to ₹1,177. Share price was steady at ₹963 over the past week.Price Target Changed • Feb 18Price target decreased to ₹1,177Down from ₹1,280, the current price target is an average from 18 analysts. New target price is 22% above last closing price of ₹966. Stock is up 4.5% over the past year. The company is forecast to post earnings per share of ₹37.92 for next year compared to ₹45.01 last year.Reported Earnings • Feb 15Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹7.76 (down from ₹10.55 in 3Q 2021). Revenue: ₹14.4b (up 2.4% from 3Q 2021). Net income: ₹1.97b (down 26% from 3Q 2021). Profit margin: 14% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 60%. Over the next year, revenue is forecast to grow 14%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 10Ipca Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022Ipca Laboratories Limited announced that they will report Q3, 2022 results on Feb 14, 2022お知らせ • Nov 24Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million.Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million on November 24, 2021. Under the terms of the consideration, the offer will be settled for a payment of INR 130.5 per share acquired. In a related transaction, Ipca is acquiring 4.8 million shares in Lyka in an open market transaction. The transaction was approved by Ipca board of directors. Satish Kumar of Arihant Capital Markets Limited acted as manager to the offer.Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improved over the past weekAfter last week's 85% share price gain to ₹2,030, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 424% over the past three years.Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS ₹19.73 (vs ₹21.08 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹15.6b (up 15% from 2Q 2021). Net income: ₹2.50b (down 6.3% from 2Q 2021). Profit margin: 16% (down from 20% in 2Q 2021). The decrease in margin was driven by higher expenses.Price Target Changed • Aug 25Price target increased to ₹2,442Up from ₹2,276, the current price target is an average from 17 analysts. New target price is approximately in line with last closing price of ₹2,482. Stock is up 24% over the past year.Recent Insider Transactions • Aug 14Insider recently sold ₹3.8m worth of stockOn the 12th of August, Anil Pareek sold around 2k shares on-market at roughly ₹2,383 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹79m more than they bought in the last 12 months.Reported Earnings • Aug 06First quarter 2022 earnings released: EPS ₹24.18 (vs ₹28.18 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹15.9b (up 9.6% from 1Q 2021). Net income: ₹3.07b (down 14% from 1Q 2021). Profit margin: 19% (down from 25% in 1Q 2021). The decrease in margin was driven by higher expenses.お知らせ • Jun 12Ipca Laboratories Limited (BSE:524494) acquired 13.09% stake in Trophic Wellness Pvt. Ltd. INR 210 million.Ipca Laboratories Limited (BSE:524494) acquired 13.09% stake in Trophic Wellness Pvt. Ltd. INR 210 million on June 11, 2021. With this transaction, Ipca Laboratories Limited increased its stake to 52.35%. Trophic Wellness will now operates as a subsidiary of Ipca Laboratories. Trophic Wellness generated a total income of INR 1,028.2 million, EBIDTA of INR 32.91 million and Net income of INR 21.76 million for the financial year ended March 31, 2021. Ipca Laboratories Limited (BSE:524494) completed the acquisition of 13.09% stake in Trophic Wellness Pvt. Ltd. on June 11, 2021.Reported Earnings • May 29Full year 2021 earnings released: EPS ₹90.11 (vs ₹47.99 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹54.8b (up 18% from FY 2020). Net income: ₹11.4b (up 88% from FY 2020). Profit margin: 21% (up from 13% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year and the company’s share price has also increased by 44% per year.Recent Insider Transactions • Apr 04Insider recently bought ₹1.9m worth of stockOn the 26th of March, Goutam Muhuri bought around 1k shares on-market at roughly ₹1,887 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹75m more in shares than they bought in the last 12 months.Recent Insider Transactions • Feb 28Compliance Officer recently sold ₹13m worth of stockOn the 23rd of February, Harish Kamath sold around 7k shares on-market at roughly ₹1,819 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹77m more than they bought in the last 12 months.Is New 90 Day High Low • Feb 20New 90-day low: ₹1,847The company is down 14% from its price of ₹2,143 on 21 November 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹1,043 per share.Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹21.09 (vs ₹15.63 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹14.1b (up 16% from 3Q 2020). Net income: ₹2.65b (up 34% from 3Q 2020). Profit margin: 19% (up from 16% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year and the company’s share price has also increased by 46% per year.Analyst Estimate Surprise Post Earnings • Feb 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Over the next year, revenue is forecast to grow 12%, compared to a 12% growth forecast for the Pharmaceuticals industry in India.Is New 90 Day High Low • Jan 25New 90-day low: ₹1,981The company is down 17% from its price of ₹2,376 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹1,038 per share.お知らせ • Jan 19Ipca Laboratories Limited to Report Q3, 2021 Results on Feb 04, 2021Ipca Laboratories Limited announced that they will report Q3, 2021 results on Feb 04, 2021株主還元524494IN PharmaceuticalsIN 市場7D6.7%0.8%0.8%1Y28.3%11.6%-1.2%株主還元を見る業界別リターン: 524494過去 1 年間で11.6 % の収益を上げたIndian Pharmaceuticals業界を上回りました。リターン対市場: 524494過去 1 年間で-1.2 % の収益を上げたIndian市場を上回りました。価格変動Is 524494's price volatile compared to industry and market?524494 volatility524494 Average Weekly Movement3.6%Pharmaceuticals Industry Average Movement6.3%Market Average Movement6.1%10% most volatile stocks in IN Market9.1%10% least volatile stocks in IN Market3.8%安定した株価: 524494 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 524494の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト194917,210Pranay Godhawww.ipca.com製薬会社であるイプカ・ラボラトリーズ・リミテッドは、インド、欧州、アフリカ、米州、アジア、CIS、オーストラレーシアにおいて、様々な治療分野向けの製剤や原薬（API）を製造・販売している。同社は、降圧剤、抗マラリア剤、利尿剤、DMARD、駆虫剤などの治療分野でAPIを提供している。また、アレルギー、抗腫瘍・抗がん剤、関節炎治療剤、抗てんかん剤、降圧剤、心臓病、糖尿病、皮膚病、糖尿病、軟膏・保護剤、発熱、消化器病、血液病、蠕虫などの治療分野において、ジェネリック医薬品やブランド製剤を提供している、血液学、蠕虫学、肝保護薬、免疫抑制薬、感染症、マラリア、神経学、神経障害性疼痛、非ステロイド性抗炎症薬、栄養補助食品、眼科、経口糖尿病薬、整形外科、プロバイオティクス、精神科、呼吸器科、リウマチ科、泌尿器科。また、世界中に製品を輸出している。年に設立され、インドのムンバイを拠点としている。もっと見るIpca Laboratories Limited 基礎のまとめIpca Laboratories の収益と売上を時価総額と比較するとどうか。524494 基礎統計学時価総額₹479.55b収益（TTM）₹11.41b売上高(TTM)₹96.47b42.0xPER（株価収益率5.0xP/Sレシオ524494 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計524494 損益計算書（TTM）収益₹96.47b売上原価₹31.62b売上総利益₹64.86bその他の費用₹53.44b収益₹11.41b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）44.98グロス・マージン67.23%純利益率11.83%有利子負債／自己資本比率7.4%524494 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.3%現在の配当利回り13%配当性向524494 配当は確実ですか？524494 配当履歴とベンチマークを見る524494 、いつまでに購入すれば配当金を受け取れますか？Ipca Laboratories 配当日配当落ち日Aug 07 2026配当支払日Sep 10 2026配当落ちまでの日数21 days配当支払日までの日数55 days524494 配当は確実ですか？524494 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/16 08:10終値2026/07/16 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ipca Laboratories Limited 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedAditya KhemkaAmbit Capitalnull nullAnand Rathi Shares and Stock Brokers Limited35 その他のアナリストを表示
Reported Earnings • Jul 11Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹96.5b (up 7.9% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year.
お知らせ • Jul 02Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026, at 15:30 Indian Standard Time.
お知らせ • Jun 27Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million.Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million on June 26, 2026. The consideration consists of common equity of Ipca Laboratories Limited at a ratio of 0.035 per common equity and convertible preferred equity of Krebs Biochemicals & Industries Limited. As part of consideration, INR 736.32 million is paid towards redeemable preference shares convertible preferred equity and INR 612 million is paid towards common equity of Krebs Biochemicals & Industries Limited. Upon completion, Ipca Laboratories Limited will own 100% stake in Krebs Biochemicals & Industries Limited. Upon merger, Krebs Biochemicals & Industries Limited would get merged with Ipca Laboratories Limited. The transaction is subject to approval of merger agreement by target board and approval of offer by acquirer board. The deal has been approved by the board. The Appointed Date for the Scheme is 1st April, 2026 and it shall be operative from the Effective Date upon receipt of all the consents and approvals as defined in the Scheme.
New Risk • Jun 05New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Declared Dividend • Jun 01Dividend of ₹6.00 announcedShareholders will receive a dividend of ₹6.00. Ex-date: 7th August 2026 Payment date: 1st January 1970 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (6% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 30Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹98.2b (up 9.8% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year and the company’s share price has also increased by 28% per year.
Reported Earnings • Jul 11Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹96.5b (up 7.9% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year.
お知らせ • Jul 02Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2026, at 15:30 Indian Standard Time.
お知らせ • Jun 27Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million.Ipca Laboratories Limited (NSEI:IPCALAB) agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited (BSE:524518) for INR 612 million on June 26, 2026. The consideration consists of common equity of Ipca Laboratories Limited at a ratio of 0.035 per common equity and convertible preferred equity of Krebs Biochemicals & Industries Limited. As part of consideration, INR 736.32 million is paid towards redeemable preference shares convertible preferred equity and INR 612 million is paid towards common equity of Krebs Biochemicals & Industries Limited. Upon completion, Ipca Laboratories Limited will own 100% stake in Krebs Biochemicals & Industries Limited. Upon merger, Krebs Biochemicals & Industries Limited would get merged with Ipca Laboratories Limited. The transaction is subject to approval of merger agreement by target board and approval of offer by acquirer board. The deal has been approved by the board. The Appointed Date for the Scheme is 1st April, 2026 and it shall be operative from the Effective Date upon receipt of all the consents and approvals as defined in the Scheme.
New Risk • Jun 05New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Declared Dividend • Jun 01Dividend of ₹6.00 announcedShareholders will receive a dividend of ₹6.00. Ex-date: 7th August 2026 Payment date: 1st January 1970 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (6% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 30Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹44.98 (up from ₹29.08 in FY 2025). Revenue: ₹98.2b (up 9.8% from FY 2025). Net income: ₹11.4b (up 55% from FY 2025). Profit margin: 12% (up from 8.3% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year and the company’s share price has also increased by 28% per year.
お知らせ • May 30Ipca Laboratories Limited Recommends Dividend for the Financial Year Ended March 31, 2026Ipca Laboratories Limited at its Board of Directors meeting holed on May 29, 2026 announced that the Board has recommended a dividend of INR 6/- per share of INR 1/- each (600%) for the financial year ended 31st March, 2026. This dividend recommended is subject to the approval of the shareholders at the ensuing Annual General Meeting. The Company has fixed 7th August, 2026 as the Record Date for the Members entitlement of dividend, if approved at the ensuing Annual General Meeting.
お知らせ • May 04Ipca Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Ipca Laboratories Limited announced that they will report Q4, 2026 results on May 29, 2026
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹12.86 (vs ₹9.78 in 3Q 2025)Third quarter 2026 results: EPS: ₹12.86 (up from ₹9.78 in 3Q 2025). Revenue: ₹24.1b (up 7.5% from 3Q 2025). Net income: ₹3.26b (up 32% from 3Q 2025). Profit margin: 14% (up from 11% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 21% per year.
お知らせ • Jan 22Ipca Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026Ipca Laboratories Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 13, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹11.14 (up from ₹9.05 in 2Q 2025). Revenue: ₹25.8b (up 9.7% from 2Q 2025). Net income: ₹2.83b (up 23% from 2Q 2025). Profit margin: 11% (up from 9.7% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 20% per year.
お知らせ • Oct 17Ipca Laboratories Limited to Report Q2, 2026 Results on Nov 13, 2025Ipca Laboratories Limited announced that they will report Q2, 2026 results on Nov 13, 2025
Reported Earnings • Aug 12First quarter 2026 earnings released: EPS: ₹9.19 (vs ₹7.58 in 1Q 2025)First quarter 2026 results: EPS: ₹9.19 (up from ₹7.58 in 1Q 2025). Revenue: ₹23.1b (up 10% from 1Q 2025). Net income: ₹2.33b (up 21% from 1Q 2025). Profit margin: 10% (in line with 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 14% per year.
Upcoming Dividend • Jul 29Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 05 August 2025. Payment date: 10 September 2025. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.8%).
お知らせ • Jul 24Ipca Laboratories Limited to Report Q1, 2026 Results on Aug 11, 2025Ipca Laboratories Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Reported Earnings • Jul 11Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₹29.08 (up from ₹21.57 in FY 2024). Revenue: ₹90.3b (up 17% from FY 2024). Net income: ₹7.38b (up 35% from FY 2024). Profit margin: 8.2% (up from 7.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • Jul 06Ipca Laboratories Limited, Annual General Meeting, Aug 11, 2025Ipca Laboratories Limited, Annual General Meeting, Aug 11, 2025, at 15:30 Indian Standard Time.
Declared Dividend • May 31Final dividend of ₹2.00 announcedDividend of ₹2.00 is the same as last year. Ex-date: 5th August 2025 Payment date: 1st January 1970 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (14% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 103% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 30Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₹29.08 (up from ₹21.57 in FY 2024). Revenue: ₹90.3b (up 17% from FY 2024). Net income: ₹7.38b (up 35% from FY 2024). Profit margin: 8.2% (up from 7.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
お知らせ • May 14Ipca Laboratories Limited to Report Q4, 2025 Results on May 29, 2025Ipca Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025
お知らせ • Mar 03Ipca Laboratories Limited Appoints Saidutta Nanda as President - Human ResourcesIpca Laboratories Limited informed that Mr. Saidutta Nanda has joined the Company as President - Human Resources with effect from 3rd March, 2025. Mr. Saidutta Nanda, aged 48 years has completed his Master of Business Administration from Institute of Management Studies, Devi Ahilya Vishwavidyalay, Indore. Mr. Nanda brings with him a professional experience of over 24 years. He started his career with Cadila Pharmaceuticals in the year 1999. Prior to joining us, he was associated with Macleods Pharmaceuticals Limited as President - Human Resources. He will be responsible for leading all the activities related to the Human Resources Division of the Company.
Reported Earnings • Feb 14Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: EPS: ₹9.78 (up from ₹7.09 in 3Q 2024). Revenue: ₹22.5b (up 9.4% from 3Q 2024). Net income: ₹2.48b (up 38% from 3Q 2024). Profit margin: 11% (up from 8.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • Jan 28Ipca Laboratories Limited to Report Q3, 2025 Results on Feb 13, 2025Ipca Laboratories Limited announced that they will report Q3, 2025 results on Feb 13, 2025
Price Target Changed • Dec 04Price target increased by 7.8% to ₹1,564Up from ₹1,452, the current price target is an average from 19 analysts. New target price is 5.0% above last closing price of ₹1,489. Stock is up 32% over the past year. The company is forecast to post earnings per share of ₹34.84 for next year compared to ₹21.57 last year.
Reported Earnings • Nov 18Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2025 results: EPS: ₹9.62 (up from ₹5.72 in 2Q 2024). Revenue: ₹23.8b (up 17% from 2Q 2024). Net income: ₹2.29b (up 58% from 2Q 2024). Profit margin: 9.6% (up from 7.1% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Declared Dividend • Nov 16Dividend of ₹2.00 announcedDividend of ₹2.00 is the same as last year. Ex-date: 25th November 2024 Payment date: 10th December 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 125% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Oct 24Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024Ipca Laboratories Limited announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Sep 20Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024Ipca Laboratories Limited announced that The second term of appointment of Dr. (Ms.) Manisha Premnath as an independent director of the Company is ending on September 20, 2024. Accordingly, she ceases to be an independent director of the Company with effect from September 21, 2024. Consequently, she also ceases to be member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee of the Board with effect from September 21, 2024. Consequent to the above, the revised composition of the Board of Directors of the Company with effect from September 21, 2024 is as follows: Mr. Premchand Godha, Executive Chairman. Mr. A.K. Jain, Managing Director /CFO. Mr. Pranay Godha, Managing Director /CEO. Mr. Prashant Godha, Executive Director. Mr. Kamal Kishore Seth, Independent Director. Dr. Narendra Mairpady, Independent Director. Dr. (Ms.) Swati Patankar, Independent Director. Mr. Vivek Shiralkar, Independent Director.
Price Target Changed • Aug 17Price target increased by 8.6% to ₹1,320Up from ₹1,216, the current price target is an average from 18 analysts. New target price is approximately in line with last closing price of ₹1,335. Stock is up 52% over the past year. The company is forecast to post earnings per share of ₹35.26 for next year compared to ₹21.57 last year.
お知らせ • Aug 14Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent DirectorIpca Laboratories Limited announced that at its AGM held on 13 August 2024, the shareholders approved appointment of Mr. Vivek Shiralkar as an independent director of the company for a period of five consecutive years from 29 May 2024 to 28 May 2029.
Upcoming Dividend • Jul 30Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 06 August 2024. Payment date: 10 September 2024. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%).
お知らせ • Jul 24Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024Ipca Laboratories Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • Jul 20Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: EPS: ₹21.57 (up from ₹18.58 in FY 2023). Revenue: ₹77.1b (up 23% from FY 2023). Net income: ₹5.47b (up 16% from FY 2023). Profit margin: 7.1% (down from 7.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
お知らせ • Jul 12Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024, at 15:30 Indian Standard Time.
Board Change • Jul 05Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Swati Patankar was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 30Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024Ipca Laboratories Limited has recommended a final dividend of INR 21 per share (200%) for the financial year ended March 31, 2024. This dividend is subject to the approval of the shareholders at the upcoming annual general meeting.
Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)Full year 2024 results: EPS: ₹25.82 (up from ₹18.58 in FY 2023). Revenue: ₹78.3b (up 25% from FY 2023). Net income: ₹5.47b (up 16% from FY 2023). Profit margin: 7.0% (down from 7.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • May 09Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024Ipca Laboratories Limited announced that they will report Q4, 2024 results on May 29, 2024
お知らせ • Mar 30+ 1 more updateIpca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent DirectorIpca Laboratories Limited announced that second term of appointment of Mr. Anand T. Kusre as an independent director of the Company is coming to an end on 31 March, 2024. Accordingly, he ceases to be an independent director of the Company with effect from 1 April, 2024. Consequent to the above, the revised composition of the Board of Directors of the Company with effect from 1st April, 2024 is as under: Mr. Premchand Godha Executive Chairman, Mr. A.K. Jain Managing Director /CFO, Mr. Pranay Godha Managing Director /CEO, Mr. Prashant Godha Executive Director, Dr. (Ms.) Manisha Premnath Independent Director, Mr. Kamal Kishore Seth Independent Director, Dr. Narendra Mairpady Independent Director and Dr. (Ms.) Swati Patankar Independent Director.
Price Target Changed • Feb 17Price target increased by 9.1% to ₹1,097Up from ₹1,006, the current price target is an average from 18 analysts. New target price is 12% below last closing price of ₹1,241. Stock is up 49% over the past year. The company is forecast to post earnings per share of ₹25.84 for next year compared to ₹18.58 last year.
Reported Earnings • Feb 15Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: ₹7.09 (up from ₹4.25 in 3Q 2023). Revenue: ₹20.8b (up 34% from 3Q 2023). Net income: ₹1.80b (up 67% from 3Q 2023). Profit margin: 8.7% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Jan 23Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024Ipca Laboratories Limited announced that they will report Q3, 2024 results on Feb 14, 2024
Recent Insider Transactions • Nov 22CFO, MD & Executive Director recently sold ₹22m worth of stockOn the 17th of November, Ajit Kumar Jain sold around 20k shares on-market at roughly ₹1,082 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ajit Kumar's only on-market trade for the last 12 months.
Price Target Changed • Nov 17Price target increased by 9.7% to ₹987Up from ₹900, the current price target is an average from 18 analysts. New target price is 8.6% below last closing price of ₹1,079. Stock is up 25% over the past year. The company is forecast to post earnings per share of ₹27.89 for next year compared to ₹18.58 last year.
Upcoming Dividend • Nov 15Upcoming dividend of ₹2.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 22 November 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 10% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).
Reported Earnings • Nov 11Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: EPS: ₹5.72 (up from ₹5.67 in 2Q 2023). Revenue: ₹20.7b (up 30% from 2Q 2023). Net income: ₹1.45b (flat on 2Q 2023). Profit margin: 7.0% (down from 9.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • Oct 26Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023Ipca Laboratories Limited announced that they will report Q2, 2024 results on Nov 10, 2023
お知らせ • Oct 17Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)Ipca Laboratories Limited announced that Mr. Hitesh Kumar Maheshwari has joined the Company as President R&D (Formulations) with effect from 16 October, 2023. Mr. Hitesh Maheshwari, aged 49 years has completed his B. Pharm from Devi Ahilya Vishwavidyalaya, Indore and M.Pharm from Panjab University, Chandigarh. Mr. Maheshwari brings with him a professional experience of over 24 years. He started his career with Ranbaxy Laboratories in the year 1999 and thereafter worked with Zydus Cadila Healthcare Ltd., Hikma Pharmaceuticals Ltd., Astron Research Ltd. and Macleods Pharmaceuticals Ltd. Prior to joining us, he was associated with Torrent Pharmaceuticals Ltd. as Executive Director and Head R&D (Formulations). He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company.
お知らせ • Jul 24Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023Ipca Laboratories Limited announced that they will report Q1, 2024 results on Aug 10, 2023
Reported Earnings • Jul 14Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: ₹18.58 (down from ₹34.85 in FY 2022). Revenue: ₹62.5b (up 7.2% from FY 2022). Net income: ₹4.71b (down 47% from FY 2022). Profit margin: 7.5% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 26 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 06Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023, at 15:30 Indian Standard Time.
Reported Earnings • May 30Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: ₹18.58 (down from ₹34.85 in FY 2022). Revenue: ₹63.7b (up 9.3% from FY 2022). Net income: ₹4.71b (down 47% from FY 2022). Profit margin: 7.4% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • May 13Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023Ipca Laboratories Limited announced that they will report Q4, 2023 results at 12:08 PM, Indian Standard Time on May 29, 2023
Price Target Changed • Apr 30Price target decreased by 8.1% to ₹851Down from ₹925, the current price target is an average from 19 analysts. New target price is 20% above last closing price of ₹710. Stock is down 30% over the past year. The company is forecast to post earnings per share of ₹23.52 for next year compared to ₹34.85 last year.
Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹701, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Pharmaceuticals industry in India. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹291 per share.
Reported Earnings • Feb 15Third quarter 2023 earnings: EPS misses analyst expectationsThird quarter 2023 results: EPS: ₹4.25 (down from ₹7.76 in 3Q 2022). Revenue: ₹15.5b (up 8.1% from 3Q 2022). Net income: ₹1.08b (down 45% from 3Q 2022). Profit margin: 7.0% (down from 14% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 33%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 21Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023Ipca Laboratories Limited announced that they will report Q3, 2023 results on Feb 14, 2023
お知らせ • Dec 20Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million on December 16, 2022. Ipca Laboratories Limited (BSE:524494) now holds 58.88% of the paid-up equity share capital of said company. Ipca Laboratories Limited (BSE:524494) completed the acquisition of additional 6.53% stake in Trophic Wellness Pvt. Ltd. on December 16, 2022.
Major Estimate Revision • Nov 18Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ₹64.0b to ₹62.9b. EPS estimate also fell from ₹33.10 per share to ₹27.90 per share. Net income forecast to grow 43% next year vs 42% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹1,000 to ₹964. Share price was steady at ₹865 over the past week.
Upcoming Dividend • Nov 16Upcoming dividend of ₹4.00 per shareEligible shareholders must have bought the stock before 22 November 2022. Payment date: 07 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%).
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 6 highly experienced directors. Additional Independent Director Narendra Mairpady was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹5.67 (down from ₹9.87 in 2Q 2022). Revenue: ₹16.4b (up 6.0% from 2Q 2022). Net income: ₹1.44b (down 43% from 2Q 2022). Profit margin: 8.8% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 11Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022Ipca Laboratories Limited announced that its Board has declared an interim dividend of INR 4 per share (400%) for the financial year 2022-23. Kindly note that vide company letter dated November 2, 2022, it had already informed that 23rd November, 2022 has been fixed as the Record Date for ascertaining the members entitlement of said interim dividend now declared which will be paid by the company to the eligible shareholders on or before 7th December, 2022.
お知らせ • Nov 03Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022Ipca Laboratories Limited announced that they will report Q2, 2023 results on Nov 11, 2022
お知らせ • Oct 21Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent DirectorIpca Laboratories Limited appointed Dr. Narendra Mairpady (DIN 00536905) as an Additional Director of the Company with effect from 20th October, 2022. He is also appointed as an Independent Director of the Company for a period of 5 years from 20th October, 2022 till 19th October, 2027. This appointment is subject to the approval of shareholders. Dr. Narendra Mairpady, aged 68 years, is a Commerce Graduate and also holds a Bachelor of Law Degree from Mysore University. He is also a certified CAIIB from the Institure of Banking. He has also obtained his Doctor Letters from Hindustan University, Chennai and Kalpagam University, Coimbatore. Consequent to the above, the revised composition of the Board of Directors of the Company with effect from 20th October, 2022 will be: Mr. Premchand Godha- Chairman & Managing Director /CEO; Mr. A.K. Jain- Joint Managing Director /CFO; Mr. Pranay Godha- Executive Director; Mr. Prashant Godha Executive Director; Mr. Anand T. Kusre - Independent Director; Dr. (Ms.) Manisha Premnath Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. Narendra Mairpady - Independent Director. The Board has also re-constituted its following committees with effect from 20th October, 2022 and the revised Board Committees will now comprise of the following Board Members: Audit Committee; Mr. Anand T. Kusre - Chairman of the Committee /Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. Narendra Mairpady - Independent Director; Mr. Prashant Godha - Executive Director; Nomination and Remuneration Committee: Mr. Anand T. Kusre Chairman of the Committee /Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. (Ms.) Manisha Premnath - Independent Director; Dr. Narendra Mairpady - Independent Director.
Recent Insider Transactions • Sep 21Insider recently sold ₹1.7m worth of stockOn the 15th of September, E. Babu sold around 2k shares on-market at roughly ₹874 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.
Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 EPS estimate fell from ₹37.84 to ₹32.15 per share. Revenue forecast steady at ₹64.0b. Net income forecast to grow 24% next year vs 30% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹1,063 to ₹1,038. Share price fell 6.7% to ₹926 over the past week.
お知らせ • Aug 12Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022Ipca Laboratories Limited at annual general meeting held on 10 August 2022, approved the confirmation of Interim dividend of INR 8/- per equity share as final dividend for the financial year ended 31st March, 2022.
Buying Opportunity • Aug 08Now 20% undervaluedOver the last 90 days, the stock is up 3.9%. The fair value is estimated to be ₹1,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.
お知らせ • Aug 05Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent DirectorIpca Laboratories Limited announced demise of Independent Director, Mr. Dev Parkash Yadava on the evening of August 2, 2022, at Mumbai. Mr. Yadava was the Non-Executive and Independent Director of the Company since April 2012.
お知らせ • Jul 30Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022Ipca Laboratories Limited announced that they will report Q1, 2023 results at 12:15 PM, Indian Standard Time on Aug 10, 2022
Buying Opportunity • Jul 21Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 2.1%. The fair value is estimated to be ₹1,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.
Reported Earnings • Jul 16Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: ₹34.85 (down from ₹45.01 in FY 2021). Revenue: ₹58.3b (up 7.6% from FY 2021). Net income: ₹8.84b (down 22% from FY 2021). Profit margin: 15% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 28 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 10%, compared to a 12% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 08Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022, at 15:30 Indian Standard Time.
Buying Opportunity • Jun 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be ₹1,132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 23%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.
Price Target Changed • May 30Price target decreased to ₹1,067Down from ₹1,162, the current price target is an average from 19 analysts. New target price is 18% above last closing price of ₹901. Stock is down 13% over the past year. The company is forecast to post earnings per share of ₹37.13 for next year compared to ₹34.85 last year.
Reported Earnings • May 26Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: ₹34.85 (down from ₹45.01 in FY 2021). Revenue: ₹58.3b (up 7.5% from FY 2021). Net income: ₹8.84b (down 22% from FY 2021). Profit margin: 15% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 8.8%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 6 highly experienced directors. Independent Director Kamal Seth was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Mar 23CFO, Joint MD & Executive Director recently sold ₹21m worth of stockOn the 17th of March, Ajit Kumar Jain sold around 20k shares on-market at roughly ₹1,027 per share. This was the largest sale by an insider in the last 3 months. Ajit Kumar has been a seller over the last 12 months, reducing personal holdings by ₹45m.
Major Estimate Revision • Feb 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from ₹45.80 to ₹37.92 per share. Revenue forecast steady at ₹58.7b. Net income forecast to grow 22% next year vs 23% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹1,280 to ₹1,177. Share price was steady at ₹963 over the past week.
Price Target Changed • Feb 18Price target decreased to ₹1,177Down from ₹1,280, the current price target is an average from 18 analysts. New target price is 22% above last closing price of ₹966. Stock is up 4.5% over the past year. The company is forecast to post earnings per share of ₹37.92 for next year compared to ₹45.01 last year.
Reported Earnings • Feb 15Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹7.76 (down from ₹10.55 in 3Q 2021). Revenue: ₹14.4b (up 2.4% from 3Q 2021). Net income: ₹1.97b (down 26% from 3Q 2021). Profit margin: 14% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 60%. Over the next year, revenue is forecast to grow 14%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 10Ipca Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022Ipca Laboratories Limited announced that they will report Q3, 2022 results on Feb 14, 2022
お知らせ • Nov 24Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million.Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million on November 24, 2021. Under the terms of the consideration, the offer will be settled for a payment of INR 130.5 per share acquired. In a related transaction, Ipca is acquiring 4.8 million shares in Lyka in an open market transaction. The transaction was approved by Ipca board of directors. Satish Kumar of Arihant Capital Markets Limited acted as manager to the offer.
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improved over the past weekAfter last week's 85% share price gain to ₹2,030, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 424% over the past three years.
Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS ₹19.73 (vs ₹21.08 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹15.6b (up 15% from 2Q 2021). Net income: ₹2.50b (down 6.3% from 2Q 2021). Profit margin: 16% (down from 20% in 2Q 2021). The decrease in margin was driven by higher expenses.
Price Target Changed • Aug 25Price target increased to ₹2,442Up from ₹2,276, the current price target is an average from 17 analysts. New target price is approximately in line with last closing price of ₹2,482. Stock is up 24% over the past year.
Recent Insider Transactions • Aug 14Insider recently sold ₹3.8m worth of stockOn the 12th of August, Anil Pareek sold around 2k shares on-market at roughly ₹2,383 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹79m more than they bought in the last 12 months.
Reported Earnings • Aug 06First quarter 2022 earnings released: EPS ₹24.18 (vs ₹28.18 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹15.9b (up 9.6% from 1Q 2021). Net income: ₹3.07b (down 14% from 1Q 2021). Profit margin: 19% (down from 25% in 1Q 2021). The decrease in margin was driven by higher expenses.
お知らせ • Jun 12Ipca Laboratories Limited (BSE:524494) acquired 13.09% stake in Trophic Wellness Pvt. Ltd. INR 210 million.Ipca Laboratories Limited (BSE:524494) acquired 13.09% stake in Trophic Wellness Pvt. Ltd. INR 210 million on June 11, 2021. With this transaction, Ipca Laboratories Limited increased its stake to 52.35%. Trophic Wellness will now operates as a subsidiary of Ipca Laboratories. Trophic Wellness generated a total income of INR 1,028.2 million, EBIDTA of INR 32.91 million and Net income of INR 21.76 million for the financial year ended March 31, 2021. Ipca Laboratories Limited (BSE:524494) completed the acquisition of 13.09% stake in Trophic Wellness Pvt. Ltd. on June 11, 2021.
Reported Earnings • May 29Full year 2021 earnings released: EPS ₹90.11 (vs ₹47.99 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹54.8b (up 18% from FY 2020). Net income: ₹11.4b (up 88% from FY 2020). Profit margin: 21% (up from 13% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year and the company’s share price has also increased by 44% per year.
Recent Insider Transactions • Apr 04Insider recently bought ₹1.9m worth of stockOn the 26th of March, Goutam Muhuri bought around 1k shares on-market at roughly ₹1,887 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹75m more in shares than they bought in the last 12 months.
Recent Insider Transactions • Feb 28Compliance Officer recently sold ₹13m worth of stockOn the 23rd of February, Harish Kamath sold around 7k shares on-market at roughly ₹1,819 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹77m more than they bought in the last 12 months.
Is New 90 Day High Low • Feb 20New 90-day low: ₹1,847The company is down 14% from its price of ₹2,143 on 21 November 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹1,043 per share.
Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹21.09 (vs ₹15.63 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹14.1b (up 16% from 3Q 2020). Net income: ₹2.65b (up 34% from 3Q 2020). Profit margin: 19% (up from 16% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year and the company’s share price has also increased by 46% per year.
Analyst Estimate Surprise Post Earnings • Feb 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Over the next year, revenue is forecast to grow 12%, compared to a 12% growth forecast for the Pharmaceuticals industry in India.
Is New 90 Day High Low • Jan 25New 90-day low: ₹1,981The company is down 17% from its price of ₹2,376 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹1,038 per share.
お知らせ • Jan 19Ipca Laboratories Limited to Report Q3, 2021 Results on Feb 04, 2021Ipca Laboratories Limited announced that they will report Q3, 2021 results on Feb 04, 2021
